Article

Pfizer-J&J Drop Alzheimer's Drug Studies After Failure

Pfizer (PFE)

Johnson & Johnson (JNJ)

Inc., and Elan Corp. ended most plans to develop an Alzheimer’s drug after a second trial failure, a blow to the companies’ efforts to market the first product to slow progress of the disease.

Bapineuzumab, designed to attack the brain plaques that serve as a hallmark of Alzheimer’s, failed to improve symptoms of dementia in the second of four final-stage trials of the drug, Pfizer and J&J said yesterday in statements. Elan’s American depositary receipts fell 11 percent to $10.02 at 9:44 a.m. New York time.

Read the full story: http://tinyurl.com/9lst2tr

Source: Bloomberg

Related Videos
Shawn Griffin, MD, sitting for a video interview
5 experts are featured in this series
5 experts are featured in this series
Christine Funke, MD
John Michael O'Brien, PharmD, MPH
Kathi Henson, MBA, sitting for a video interview
Mike Fazio, Navista, Cardinal Health
1 expert in this video
1 expert in this video
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo